Alicja Steiner, MD
Pain Medicine · San Diego, CANPI 1851309314
Payments from drug & device makers
Across 636 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Scilex Pharmaceuticals Inc.$936
- Boston Scientific$867
- Teva Pharmaceuticals USA, Inc.$751
- plus $6K from 37 others
What the payments were for
- Consulting fees$1,2008%
- Travel & lodging$2812%
- Food & beverage$12,91289%
- Education$700%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$2,013
- UBRELVY$477
- iFuse Implant$257
- AJOVY$225
- WaveWriter Alpha Prime 16$167
- Omnia$132
- VYEPTI$125
- MOVANTIK$125
- QULIPTA$123
- Wegovy$121
- Zilretta$117
- TARGETSTIM$113
- NEOX$110
- CLARIX$110
- StimQ Receiver Stimulator Kit Channel A US w Receiver$106
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$106
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$106
- Freedom 4A Receiver Kit Channel A US w Receiver$106
- Freedom 8A Receiver Kit Channel A US w Receiver$106
How this compares
$14,464 in reported general payments places this provider in the 85th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 300 | $239,536 |
| ZtlidoLidocaine | 176 | $143,109 |
| RelistorMethylnaltrexone Bromide | 41 | $92,427 |
| UbrelvyUbrogepant | 55 | $71,498 |
| Buprenorphine | 232 | $55,464 |
| Emgality PenGalcanezumab-Gnlm | 69 | $46,891 |
| Lidocaine | 326 | $44,561 |
| Nurtec OdtRimegepant Sulfate | 36 | $43,262 |
| Naloxone Hcl | 413 | $24,009 |
| HorizantGabapentin Enacarbil | 26 | $21,250 |
| BotoxOnabotulinumtoxina | 14 | $16,006 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 846 | $15,493 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 537 | $13,608 |
| OxycontinOxycodone Hcl | 27 | $12,760 |
| KloxxadoNaloxone Hcl | 105 | $12,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er | $728 | $247,891314 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $936 | $143,109176 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,434 | $92,42741 claims |
| AbbVieUbrelvy, Botox | $1,946 | $87,50369 claims |
| Hikma Pharmaceuticals USABuprenorphine, Kloxxado | $334 | $67,975337 claims |
| PfizerNurtec Odt | $283 | $43,26236 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $64 | $21,25026 claims |
| Redhill Biopharma Inc.Movantik | $266 | $6,61518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 pain medicine providers in California.
Other pain medicine in San Diego
- Nathaniel SchusterSan Diego$366K
- Mark WallaceSan Diego$340K
- Gemayel LeeSan Diego$131K
- Clayton VargaSan Diego$112K
- Jessica OswaldSan Diego$90K
- Kevin SmithSan Diego$80K
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.